Sign up to save your podcasts
Or
Share Healthcare: ASH 2017's Big Winners And Losers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Healthcare: ASH 2017's Big Winners And Losers
Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.
View all episodes
By The Motley Fool
4.5
825825 ratings
Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.
More shows like Industry Focus
View all
Motley Fool Money
3,228 Listeners
Motley Fool Answers
807 Listeners
Rule Breaker Investing
938 Listeners
MarketFoolery
1,604 Listeners